Kurkina, Nadezhda Viktorovna, E. A. Repina, P. V. Volkova, and A. A. Repin. “Ibrutinib Efficacy in First-Line Therapy of High-Risk Patients Vs. Second- and Third-Line Therapies of Resistant Chronic Lymphocytic Leukemia”. Clinical Oncohematology 16, no. 2 (February 20, 2024): 209–212. Accessed December 12, 2024. https://bloodjournal.ru/index.php/coh/article/view/27.